Autres langues Gilead Sciences, Inc. Sao Paulo

Actions

GILD34

BRGILDBDR000

Produits pharmaceutiques

Marché Fermé - Sao Paulo 21:37:42 04/09/2026			Varia. 5j.	Varia. 1 janv.
64,26 ^BRL	+0,02%		+2,00%	+12,09%

03/09	Le traitement d'AbbVie contre le cancer du sang réduit la progression de la maladie et le risque de décès lors d'un essai clinique	RE
01/09	Les laboratoires pharmaceutiques mondiaux ayant officiellement annoncé des accords de prix avec Trump	RE

Autres langues

03/09	AbbVie's blood cancer therapy lowers disease progression, death risk in trial
01/09	Global pharma companies that have publicly announced Trump drug pricing agreements
28/08	Afternoon Meeting: Warsh entra en escena
28/08	Warsh Takes the Stage
28/08	Morning Meeting: Zwei Märkte, zwei Geschichten
28/08	A tale of two markets
28/08	Gilead Sciences : Breaks Ground on New Biologics Facility as Part of $32 Billion U.S. R&D and Manufacturing Investment
28/08	Gilead Sciences Wins FDA Approval for HIV Pill Bixlenvo
27/08	US FDA approves Gilead's once-daily combination pill for HIV treatment
27/08	U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
27/08	Gilead Sciences Announces FDA Approval Of Bixlenvo For Virologically Suppressed Adults With HIV
27/08	FDA Approves Gilead Sciences' Bixlenvo for Certain Adults With HIV
26/08	Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
25/08	Afternoon Meeting: Wall Street exige resultados
25/08	Wall Street Wants Receipts
25/08	Positief nieuws voor Lakefront uit de VS
25/08	Morning Meeting: ¿Mucho ruido y pocas nueces?
25/08	Morning Meeting: Viel Lärm um nichts?
25/08	Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US
24/08	Lakefront Gets FDA Orphan Drug Label for Gamgertamig
24/08	Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation
24/08	Gilead Sciences, Inc. Receives European Commission Approval for Trodelvy Plus Pembrolizumab in First-Line Metastatic Triple-Negative Breast Cancer
24/08	Gilead Sciences' Trodelvy Gains EU Approval for Breast Cancer
24/08	European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
19/08	Gilead Sciences Insider Sold Shares Worth $3,853,908, According to a Recent SEC Filing